Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ClinicalTrials.gov |
Last refreshed on:
|
12 December 2020 |
Main ID: |
NCT03659331 |
Date of registration:
|
28/08/2018 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease
|
Scientific title:
|
A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease |
Date of first enrolment:
|
September 2018 |
Target sample size:
|
50 |
Recruitment status: |
Unknown status |
URL:
|
https://clinicaltrials.gov/show/NCT03659331 |
Study type:
|
Interventional |
Study design:
|
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
|
Phase:
|
N/A
|
|
Contacts
|
Name:
|
Elon Pras, Prof |
Address:
|
|
Telephone:
|
972-35302998 |
Email:
|
elon.prasProf@sheba.gov.il |
Affiliation:
|
|
|
Name:
|
Elon Pras, Prof |
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
The Institute of Human Genetics, Sheba Medical Center, Israel |
| |
Key inclusion & exclusion criteria
|
Inclusion Criteria:
patients over the age of 18 unexplained elevation of liver enzymes patients that carry a
single mutation in the ATP7B gene.
-
Exclusion Criteria:
na
Age minimum:
18 Years
Age maximum:
N/A
Gender:
All
|
Health Condition(s) or Problem(s) studied
|
Wilson Disease
|
Intervention(s)
|
Dietary Supplement: Zinc
|
Primary Outcome(s)
|
measurement of liver enzymes in blood tests
[Time Frame: 9 months]
|
Secondary ID(s)
|
4987-18-SMC
|
Source(s) of Monetary Support
|
Please refer to primary and secondary sponsors
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|